If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  Predicting Pre-Eclampsia in Pregnant Women with Lupus ATLANTA, GA -- November 14, 2007 -- Researchers may be able to predict whether preeclampsia will occur in pregnant women who have SLE, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Boston, Mass. Systemic lupus erythematosus (also called SLE or lupus) is a chronic autoimmune inflammatory disease that can affect the skin, joints, kidneys, lungs, nervous system, and/or other organs of the body. The symptoms of SLE vary from mild to severe, and typically involve alternating periods of remission and relapse. Although the risks to pregnant women with SLE themselves are low, the frequency of obstetric complications, such as preeclampsia and impaired fetal growth restriction, are increased in SLE -- especially in patients with antiphospholipid antibodies (a cause of vascular inflammation and increased tendency toward blood clotting). Preeclampsia is associated with insufficient placental blood flow and abnormal placental development, and is a major cause of maternal, fetal and neonatal morbidity and mortality. New blood vessels form in growing tissues through a process known as angiogenesis. In preeclampsia, the presence of anti-angiogenic proteins in the mother's circulation prevents normal growth of blood vessels in the placenta and causes injury to kidneys and blood vessels in the mother. Patients suffering from preeclampsia develop high blood pressure and protein in the urine followed by swelling, weight gain, headaches and, in some cases, seizures. In the fetus, there is poor growth and often severe prematurity. Researchers recently studied 211 women with SLE and/or APLAs who were less than 12 weeks pregnant, and followed them through pregnancy to determine if increased levels of anti-angiogenic factors in women with lupus would predict the development of preeclampsia later in pregnancy. Subjects were enrolled in the PROMISSE Study (Predictors of pRegnancy Outcome: bioMarkers In antiphospholipid antibody Syndrome and Systemic lupus Erythematosus), a multi-center observational study funded by NIAMS. Each of the 16 patients with SLE and/or increased APLAs who developed preeclampsia were matched based on age and ethnicity to another SLE and/or APLA positive patient who did not develop preeclampsia and a non-autoimmune patient who had an uncomplicated, healthy pregnancy. Researchers noted that as early as 12 to 15 weeks into their pregnancy, women with SLE and/or APLAs showed higher levels of circulating antiangiogenic factors than participants who had healthy pregnancies. The rate of increase in circulating antiangiogenic factors through pregnancy was significantly higher in the SLE and/or APLA positive patients who went on to develop preeclampsia, and it was higher in participants with SLE and/or antiphospholipid antibodies compared to non-autoimmune participants who had healthy pregnancies. Participants with SLE and/or APLAs who had elevated circulating antiangiogenic factors at 20 to 23 weeks into their pregnancies were at markedly increased risk for preeclampsia later in their pregnancies. "These findings indicate that circulating antiangiogenic factors are early markers predictive of preeclampsia in patients with SLE," said Jane E. Salmon, MD; Collette Kean Research chair; co-director, Kirkland Center for Lupus Research; Hospital for Special Surgery. "Because inflammatory mediators trigger production of antiangiogenic factors, early intervention to block specific pathways of inflammation could prevent angiogenic imbalance in lupus pregnancies at risk for preeclampsia."
SOURCE: American College of Rheumatology
|
